Significant association between the Axin2 rs2240308 single nucleotide polymorphism and the incidence of prostate cancer

Chao Ma, Chunxiao Liu, Peng Huang, Haruki Kaku, Jie Chen, Kai Guo, Hideo Ueki, Akiko Sakai, Yasutomo Nasu, Hiromi Kumon, Kenji Shimizu, Masami Watanabe

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

The Wnt signaling pathway plays a crucial role in human cancer development, and axis inhibition protein 2 (Axin2) is a master scaffold protein involved in Wnt signaling. Axin2 negatively regulates Wnt signaling and acts as a tumor suppressor protein. The present study evaluated the association between the Axin2 single nucleotide polymorphism (SNP) rs2240308 [guanine (G)/adenine (A)] and the incidence of prostate cancer. In total, 103 patients with prostate cancer and 100 cancer-free control males were included in this case-control study, and were genotyped using the genomic DNA extracted from peripheral blood samples. The results revealed a higher incidence of prostate cancer in the subjects with the homozygous GG genotype and a reduced cancer incidence in the patients with the GA genotype of the rs2240308 SNP (G/A) in the Axin2 gene. The adjusted odds ratio for carriers with the GA genotype was 0.377 (95% CI, 0.206-0.688; P=0.001) and that for the AA genotype was 0.830 (95% CI, 0.309-2.232; P=0.712) compared with the GG genotype. Therefore, the GA genotype was found to exhibit a protective effect that decreased the risk of prostate cancer. To the best of our knowledge, this is the first study to demonstrate the significant association between this SNP (rs2240308, G/A) and the risk of prostate cancer. This association indicates the possibility that the variations in the Axin2 gene in this position may play a significant role in promoting the development of cancer in the prostate. We believe that the Axin2 SNP (rs2240308) could be a useful biomarker for the predisposition and early diagnosis of the disease.

Original languageEnglish
Pages (from-to)789-794
Number of pages6
JournalOncology Letters
Volume8
Issue number2
DOIs
Publication statusPublished - 2014

Fingerprint

Single Nucleotide Polymorphism
Prostatic Neoplasms
Genotype
Incidence
Proteins
Tumor Suppressor Proteins
Neoplasms
Wnt Signaling Pathway
Gene Order
Guanine
Human Development
Adenine
Inhibition (Psychology)
Case-Control Studies
Early Diagnosis
Biomarkers
Odds Ratio
DNA

Keywords

  • Axin2
  • Prostate cancer
  • Rs2240308
  • Single nucleotide polymorphism
  • Wnt signaling pathway

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Significant association between the Axin2 rs2240308 single nucleotide polymorphism and the incidence of prostate cancer. / Ma, Chao; Liu, Chunxiao; Huang, Peng; Kaku, Haruki; Chen, Jie; Guo, Kai; Ueki, Hideo; Sakai, Akiko; Nasu, Yasutomo; Kumon, Hiromi; Shimizu, Kenji; Watanabe, Masami.

In: Oncology Letters, Vol. 8, No. 2, 2014, p. 789-794.

Research output: Contribution to journalArticle

Ma, Chao ; Liu, Chunxiao ; Huang, Peng ; Kaku, Haruki ; Chen, Jie ; Guo, Kai ; Ueki, Hideo ; Sakai, Akiko ; Nasu, Yasutomo ; Kumon, Hiromi ; Shimizu, Kenji ; Watanabe, Masami. / Significant association between the Axin2 rs2240308 single nucleotide polymorphism and the incidence of prostate cancer. In: Oncology Letters. 2014 ; Vol. 8, No. 2. pp. 789-794.
@article{095746826b3a47ceb5b7bc1e6af3484e,
title = "Significant association between the Axin2 rs2240308 single nucleotide polymorphism and the incidence of prostate cancer",
abstract = "The Wnt signaling pathway plays a crucial role in human cancer development, and axis inhibition protein 2 (Axin2) is a master scaffold protein involved in Wnt signaling. Axin2 negatively regulates Wnt signaling and acts as a tumor suppressor protein. The present study evaluated the association between the Axin2 single nucleotide polymorphism (SNP) rs2240308 [guanine (G)/adenine (A)] and the incidence of prostate cancer. In total, 103 patients with prostate cancer and 100 cancer-free control males were included in this case-control study, and were genotyped using the genomic DNA extracted from peripheral blood samples. The results revealed a higher incidence of prostate cancer in the subjects with the homozygous GG genotype and a reduced cancer incidence in the patients with the GA genotype of the rs2240308 SNP (G/A) in the Axin2 gene. The adjusted odds ratio for carriers with the GA genotype was 0.377 (95{\%} CI, 0.206-0.688; P=0.001) and that for the AA genotype was 0.830 (95{\%} CI, 0.309-2.232; P=0.712) compared with the GG genotype. Therefore, the GA genotype was found to exhibit a protective effect that decreased the risk of prostate cancer. To the best of our knowledge, this is the first study to demonstrate the significant association between this SNP (rs2240308, G/A) and the risk of prostate cancer. This association indicates the possibility that the variations in the Axin2 gene in this position may play a significant role in promoting the development of cancer in the prostate. We believe that the Axin2 SNP (rs2240308) could be a useful biomarker for the predisposition and early diagnosis of the disease.",
keywords = "Axin2, Prostate cancer, Rs2240308, Single nucleotide polymorphism, Wnt signaling pathway",
author = "Chao Ma and Chunxiao Liu and Peng Huang and Haruki Kaku and Jie Chen and Kai Guo and Hideo Ueki and Akiko Sakai and Yasutomo Nasu and Hiromi Kumon and Kenji Shimizu and Masami Watanabe",
year = "2014",
doi = "10.3892/ol.2014.2177",
language = "English",
volume = "8",
pages = "789--794",
journal = "Oncology Letters",
issn = "1792-1074",
publisher = "Spandidos Publications",
number = "2",

}

TY - JOUR

T1 - Significant association between the Axin2 rs2240308 single nucleotide polymorphism and the incidence of prostate cancer

AU - Ma, Chao

AU - Liu, Chunxiao

AU - Huang, Peng

AU - Kaku, Haruki

AU - Chen, Jie

AU - Guo, Kai

AU - Ueki, Hideo

AU - Sakai, Akiko

AU - Nasu, Yasutomo

AU - Kumon, Hiromi

AU - Shimizu, Kenji

AU - Watanabe, Masami

PY - 2014

Y1 - 2014

N2 - The Wnt signaling pathway plays a crucial role in human cancer development, and axis inhibition protein 2 (Axin2) is a master scaffold protein involved in Wnt signaling. Axin2 negatively regulates Wnt signaling and acts as a tumor suppressor protein. The present study evaluated the association between the Axin2 single nucleotide polymorphism (SNP) rs2240308 [guanine (G)/adenine (A)] and the incidence of prostate cancer. In total, 103 patients with prostate cancer and 100 cancer-free control males were included in this case-control study, and were genotyped using the genomic DNA extracted from peripheral blood samples. The results revealed a higher incidence of prostate cancer in the subjects with the homozygous GG genotype and a reduced cancer incidence in the patients with the GA genotype of the rs2240308 SNP (G/A) in the Axin2 gene. The adjusted odds ratio for carriers with the GA genotype was 0.377 (95% CI, 0.206-0.688; P=0.001) and that for the AA genotype was 0.830 (95% CI, 0.309-2.232; P=0.712) compared with the GG genotype. Therefore, the GA genotype was found to exhibit a protective effect that decreased the risk of prostate cancer. To the best of our knowledge, this is the first study to demonstrate the significant association between this SNP (rs2240308, G/A) and the risk of prostate cancer. This association indicates the possibility that the variations in the Axin2 gene in this position may play a significant role in promoting the development of cancer in the prostate. We believe that the Axin2 SNP (rs2240308) could be a useful biomarker for the predisposition and early diagnosis of the disease.

AB - The Wnt signaling pathway plays a crucial role in human cancer development, and axis inhibition protein 2 (Axin2) is a master scaffold protein involved in Wnt signaling. Axin2 negatively regulates Wnt signaling and acts as a tumor suppressor protein. The present study evaluated the association between the Axin2 single nucleotide polymorphism (SNP) rs2240308 [guanine (G)/adenine (A)] and the incidence of prostate cancer. In total, 103 patients with prostate cancer and 100 cancer-free control males were included in this case-control study, and were genotyped using the genomic DNA extracted from peripheral blood samples. The results revealed a higher incidence of prostate cancer in the subjects with the homozygous GG genotype and a reduced cancer incidence in the patients with the GA genotype of the rs2240308 SNP (G/A) in the Axin2 gene. The adjusted odds ratio for carriers with the GA genotype was 0.377 (95% CI, 0.206-0.688; P=0.001) and that for the AA genotype was 0.830 (95% CI, 0.309-2.232; P=0.712) compared with the GG genotype. Therefore, the GA genotype was found to exhibit a protective effect that decreased the risk of prostate cancer. To the best of our knowledge, this is the first study to demonstrate the significant association between this SNP (rs2240308, G/A) and the risk of prostate cancer. This association indicates the possibility that the variations in the Axin2 gene in this position may play a significant role in promoting the development of cancer in the prostate. We believe that the Axin2 SNP (rs2240308) could be a useful biomarker for the predisposition and early diagnosis of the disease.

KW - Axin2

KW - Prostate cancer

KW - Rs2240308

KW - Single nucleotide polymorphism

KW - Wnt signaling pathway

UR - http://www.scopus.com/inward/record.url?scp=84902331662&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902331662&partnerID=8YFLogxK

U2 - 10.3892/ol.2014.2177

DO - 10.3892/ol.2014.2177

M3 - Article

AN - SCOPUS:84902331662

VL - 8

SP - 789

EP - 794

JO - Oncology Letters

JF - Oncology Letters

SN - 1792-1074

IS - 2

ER -